Publications

Osteocutaneous flap (OCF) mandible reconstruction is at high risk for surgical site infection. This study aimed to describe diagnosis, management, and outcome of OCF-related osteomyelitis. All patients managed at our institution for an OCF-related osteomyelitis following mandible reconstruction were included in a retrospective cohort study (2012-2019). Microbiology was described according to gold-standard surgical samples, considering all virulent pathogens, and potential contaminants if present on at least two samples. Determinants of treatment failure were assessed by logistic regression and Kaplan-Meier curve analysis. The 48 included patients (median age 60.5 (IQR, 52.4-66.6) years) benefited from OCF mandible reconstruction mostly for carcinoma ( n=27/48n=27/48 ; 56.3 %) or osteoradionecrosis ( n=12/48n=12/48 ; 25.0 %). OCF-related osteomyelitis was mostly early ( ≤3≤3 months post-surgery; n=43/48n=43/48 ; 89.6 %), presenting with local inflammation ( n=28/47n=28/47 ; 59.6 %), nonunion (wound dehiscence) or sinus tract ( n=28/47n=28/47 ; 59.6 %), and/or bone or device exposure ( n=21/47n=21/47 ; 44.7 %). Main implicated pathogens were Enterobacteriaceae ( n=25/41n=25/41 ; 61.0 %), streptococci ( n=22/41n=22/41 ; 53.7 %), Staphylococcus aureus ( n=10/41n=10/41 ; 24.4 %), enterococci ( n=9/41n=9/41 ; 22.0 %), non-fermenting Gram-negative bacilli ( n=8/41n=8/41 ; 19.5 %), and anaerobes ( n=8/41n=8/41 ; 19.5 %). Thirty-nine patients (81.3 %) benefited from surgery, consisting of debridement with implant retention (DAIR) in 25/3925/39 (64.1 %) cases, associated with 93 (IQR, 64-128) days of antimicrobial therapy. After a follow-up of 18 (IQR, 11-31) months, 24/4824/48 (50.0 %) treatment failures were observed. Determinants of treatment outcomes were DAIR (OR, 3.333; 95 % CI, 1.020-10.898) and an early infectious disease specialist referral (OR, 0.236 if ≤2≤2 weeks; 95 % CI, 0.062-0.933). OCF-related osteomyelitis following mandibular reconstruction represents difficult-to-treat infections. Our results advocate for a multidisciplinary management, including an early infectious-disease-specialist referral to manage the antimicrobial therapy driven by complex microbiological documentation.